The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Tough years ahead for European banks

Thu, 16th Jul 2020 12:27

Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts Joice Alves (joice.alves@thomsonreuters.com) and
Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Stefano Rebaudo
(stefano.rebaudo@thomsonreuters.com) in Milan.

TOUGH YEARS AHEAD FOR EUROPEAN BANKS (1123 GMT)

Pandemic-induced non-performing loans (NPLs) and capital erosion are the main risks for
banks across the world, as the economy will take time to get back to pre-Covid levels while
stimulus measures might not be able to fully compensate the adverse impact of the virus.

According to rating agency Moody’s, damage on asset quality, profitability and capital will
persist through 2022 for many banks.

NPLs will be significantly higher in 2022 than in 2019, rising as much as “200 basis points
or even near 300 basis points at banks in Italy, Spain or the UK”, with Italy at above 11%
followed by Spain at around 6%, in terms of NPL to gross loans ratio.

In 2022 many economies will not have recovered pre crisis GDP levels, while most of the banks
under scrutiny by Moody’s will not regain the tangible common equity (TCE) to risk weighted
asset ratio they had in 2019.

The rating agency sees a moderate increase for Spain and the UK, given “stronger income
generation of the largest banks.”

Government schemes will support the economy and indirectly banks’ balance sheets, but the
Moody’s analysis shows “moderate loan-loss relief overall from bank specific support measures”.

(Stefano Rebaudo)

*****

ARE YOU PLANNING TO BUY EXPENSIVE HANDBAGS OR WATCHES? (0827 GMT)

The absence of deep-pocketed tourists has now turned attention to local demand for luxury
goods makers, given the re-opening trends in Europe has been so far so good.

BofA's analysts are upbeat on the sector and believe any commentary around European
re-opening trends would be one of the most important catalyst for the reporting season.

But dire numbers cannot be entirely ignored. Cartier maker Richemont is among the
top fallers in Europe today with shares sliding 5.2% to two-week lows after the company said its
Q1 sales nearly halved because of COVID-19's "unprecedented" disruption.

Richemont's numbers came in a day after Burberry warned it will cut 500 jobs as it
sees slow demand recovery, particularly from deep-pocketed tourists.

BofA, which prefers LVMH and Burberry over Kering and Hugo Boss
, says local demand in Europe is driving the recovery as lockdown measures are lifted.

"Our Luxury Demand Indicator fell 53% in Apr-May, but initial Jun-July data is encouraging.
China and Korea continues to accelerate," BofA says.

It sees European luxury revenue down 57% in Q2.

Europe's top asset manager, Amundi, is also keen on the sector as it sees demand rising in
China. More here: LIVE MARKETS-What's hot and what's not in post-lockdown world

Next week, investors will be watching if Christian Dior and Moncler have
anything to say that will help get a picture of what the recovery will look like.

Here is how shares in some major European brands have bounced back nicely since the March
slump.

(Joice Alves)

*****

OPENING SNAPSHOT: HEINEKEN, A BITTER Q2 AFTERTASTE (0742 GMT)

European stocks opened down and are now falling 0.8% with an unscheduled trading update from
Heineken giving a bitter aftertaste to the beginning of the Q2 earnings season.

The Dutch brewer lost over 5% after announcing first-half net revenue fell 16.4% as the
impact of coronavirus-related lockdowns intensified in the second quarter.

No sign of a dynamic V-shaped recovery here even if the end of the quarter saw some
improvement: "After a low point in April, volume started to gradually recover into June as
lockdowns were lifted around the world and customers restored depleted inventories".
Anyhow, the tone ain't particularly merry with another big name, luxury goods group Richemont
giving no sign of a V-shaped recovery - actually no outlook at all - and reporting
"unprecedented levels of disruption" from the COVID-19 pandemic.

Not that Getinge won't cheer up the mood that much: the Swedish medical equipment maker is
up about 4% but that's on a jump in core profit due to high demand for...ventilators.

Another group in the healthcare space jumped: Germany's Sartorius which raised its forecast
for the year.

Among other big losers, there's Ladbrokes owner GVC down 6.5% after announcing that Kenneth
Alexander will step down as chief executive officer after 13 years at the helm.

(Julien Ponthus)

*****

ON THE RADAR: ANOTHER EARLY BATCH OF Q2 EARNINGS (0636 GMT)

European shares are seen opening in the red as risk appetite took a hit by concerns about
deteriorating U.S.-China relations. Investors also have to digest a slew of earnings reports,
which show the size of lockdowns damage.

France's Alstom reports a 27% slump in Q1 sales while Richemont Q1 sales nearly halve after
COVID-19 disruption. Richemont shares are down 4% in pre-market trading.

On a brighter note, Norway's Telenor Q2 earnings beat estimates and the company said it
expects a single-digit decline in its subscription and traffic revenues this year. Experian
first-quarter revenue falls less than feared.

Germany's Zalando shares are up almost 5% in pre market after the online fashion retailer
raised full year guidance as more people shop online.

Global miner Anglo sticks to most of its 2020 output targets but Q2 hit by COVID-19.

Swedish medical equipment maker Getinge also reported a jump in core profit and
order intake in the second quarter as demand for ventilators and other life support equipment
surged.

More news about COVID-19 treatment and vaccine: Early-stage human trial data on a vaccine
being developed by AstraZeneca and Oxford University will be published on July 20, The
Lancet medical journal said. Novartis's Sandoz division says will not make a profit on
15 generic drugs it is making available to developing countries to treat symptoms of COVID-19,
the Swiss drugmaker said on Thursday.

(Joice Alves)

*****

MORNING CALL: U.S.-CHINA TENSIONS HIT ONE MORE TIME (0540 GMT)

European shares are seen opening in the red as risk appetite weakened by growing concerns
about deteriorating U.S.-China relations.

Worries about a dispute between the world's two largest economies over the control of
advanced technologies and the protection of civil liberties in Hong Kong pushed Asian stocks and
U.S. futures down.

Even news that China's economy rebounded more than hoped in the second quarter from a record
slump was not enough to cheer investors up. A surge in coronavirus cases, which is prompting
some governments to reimpose containment measures, is also not helping sentiment.

After touching a one-month highs yesterday on vaccine hopes, European markets are set to
follow Asia lower. Investors will also have to digest a slew of earnings, which will show the
size of lockdowns damage.

Financial spreadbetters at IG expect London's FTSE to open 20 points lower at 6,273,
Frankfurt's DAX to open 97 points lower at 12,834 and Paris' CAC to open 26 points lower at
5,083.

(Joice Alves)

*****

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.